Brief by Shorts91 Newsdesk / 04:34am on 01 May 2024,Wednesday Health & Wellness
Amidst concerns over rare blood clot side effects, AstraZeneca reiterates its focus on patient safety for its Covid-19 vaccine. The UK-headquartered pharmaceutical company extends sympathy to affected individuals while stressing adherence to stringent regulatory standards. AstraZeneca's vaccine, known as Covishield in India, faces scrutiny after acknowledging the potential for clot-related side effects in very rare cases. Court documents reveal the admission, although the causal link remains unclear. The World Health Organization identifies thrombosis with thrombocytopenia syndrome (TTS) as a new adverse event post-immunization with adenovirus vector-based Covid-19 vaccines. AstraZeneca maintains its commitment to safety amidst ongoing investigations into the vaccine's rare side effects.
